Cutaneous T-cell lymphoma
The PBS subsidises vorinostat for patients with cutaneous T-cell lymphoma (CTCL).
Treatment with vorinostat can be subsidised through the Pharmaceutical Benefits Scheme (PBS) under section 85 of the National Health Act 1953 for patients with CTCL.
Patients must meet the relevant criteria in the restrictions and be eligible for the PBS.
The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing vorinostat.
Make all initial applications for authority approval to prescribe vorinostat for the treatment of CTCL in writing and:
- upload through Health Professional Online Services, or
- post to the PBS Complex Drugs Programs address
All applications must include a completed:
- authority prescription form, and
- Cutaneous T-cell lymphoma (CTCL) initial PBS authority application form
Applications for continuing treatment can be made by calling the PBS Complex Drugs Programs enquiry line.
For more information contact the PBS Complex Drugs Programs enquiry line.